A Technical Assessment of a Commercial GFAP Lateral Flow Assay to Establish Proof-of-Concept for Use in Traumatic Brain Injury.

ABSTRACT: Glial fibrillary acidic protein (GFAP) is an emerging biomarker for the detection of acute intracranial pathology following acute brain injuries such as traumatic brain injury (TBI), stroke, and hypoxic-ischaemic encephalopathy. We undertake a proof-of-concept technical assessment of a commercial lateral flow test (LFT) for the detection of GFAP [the Upfront DX LVOne GFAP lateral flow assay (LFA)], against GFAP concentrations measured using a gold-standard assay [Single Molecule Arrays (Simoa®)-based Human Neurology 4-Plex B assay] in a TBI population. The ability of the LVOne GFAP LFA for identification of samples with GFAP concentrations above the manufacturer's reported lower limit of detection (≥ 0.2 ng/ml) was assessed, with further assessment of the association between the LVOne and

SUBMITTER: Whitehouse DP 

PROVIDER: S-EPMC12255627 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature